Prelude Therapeutics (PRLD) vs Relmada Therapeutics (RLMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed Relmada Therapeutics (RLMD) over the past year, gaining 93.4% versus a loss of 38.6%. Over five years, PRLD leads with a -76.9% price change compared with -86.1% for RLMD. Relmada Therapeutics is the larger company by market cap ($279.5 million vs $258.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRLD | RLMD |
|---|---|---|
| Share price | $3.23 | $2.62 |
| Market cap | $258.63M | $279.54M |
| 1-day change | -0.77% | -15.76% |
| YTD return | +11.38% | -45.76% |
| 1-year return | +93.41% | -38.64% |
| 5-year return | -76.93% | -86.09% |
| EPS (TTM) | $-0.59 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $12.14M | — |
| Revenue growth (YoY) | +73.43% | — |
| Net income (latest FY) | $-99.50M | $-57.39M |
| Operating margin | -861.33% | — |
| Net margin | -819.59% | — |
| 52-week high | $6.83 | $8.00 |
| 52-week low | $1.30 | $2.60 |
| Distance from 52-week high | -52.71% | -67.25% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +172.45% | +310.31% |
| Average volume | 432.74K | 1.45M |
| Shares outstanding | 65.34M | 106.69M |
| Employees | 79 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed RLMD by 132.1 percentage points over the past year.
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About Relmada Therapeutics
RLMD stock →Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
PRLD vs RLMD FAQ
Which is bigger, Prelude Therapeutics or Relmada Therapeutics?
Relmada Therapeutics (RLMD) is larger, with a market capitalization of $279.54M compared with $258.63M for Prelude Therapeutics (PRLD).
Which stock has performed better over the past year, PRLD or RLMD?
PRLD returned +93.41% over the past 12 months, compared with -38.64% for RLMD (price return, excluding dividends). Past performance does not predict future results.
Are Prelude Therapeutics and Relmada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.